Galectin-3 in cardiac remodeling and heart failure

Rudolf A. De Boer, Lili Yu, Dirk J. Van Veldhuisen

Research output: Contribution to journalReview articlePopular

201 Citations (Scopus)

Abstract

Galectin-3 is a member of the galectin family, which consists of animal lectins that bind β-galactosides. Recently, a role for galectin-3 in the pathophysiology of heart failure has been suggested. It was observed that galectin-3 is specifically upregulated in decompensated heart failure compared with compensated heart failure in animal models of heart failure. This has been associated with activation of fibroblasts and macrophages, which are a hallmark of cardiac remodeling. Therefore, galectin-3 may be a culprit biomarker in heart failure. Initial clinical observations indicate that galectin-3 may be a useful biomarker for decompensated heart failure, with incremental value over well-used "pressure-dependent" biomarkers, such as B-type natriuretic peptide. Future studies should focus on galectin-3 biology to better address the usefulness of galectin-3 as a biomarker and probe the usefulness of anti-galectin-3 therapy in treating heart failure.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Heart Failure Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Mar 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Galectin-3 in cardiac remodeling and heart failure'. Together they form a unique fingerprint.

Cite this